- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: Fezakinumab is a fully human monoclonal anti-IL22 antibody being investigated for clinical antiinflammatory utility against acute and chronic conditions.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequences identical to those of the heavy and light variable regions of fezakinumab are claimed in patent US7811567, leading to identification of clone 356A11 as fezakinumab .
|No information available.|
|Summary of Clinical Use|
|Fezakinumab (ILV-094) has reached Phase 2 for atopic dermatitis (NCT01941537 ongoing), rheumatoid arthritis (NCT00883896 completed) and Phase 1 for psoriasis (NCT00563524 completed).|
|Mechanism Of Action and Pharmacodynamic Effects|
|IL-22, an IL-10 superfamily cytokine, plays a key role during inflammatory responses. Blocking or neutralising anti-IL-22 antibodies inhibit IL-22 activity, thereby reducing inflammation. Fezakinumab binds IL-22, effectively preventing formation of the IL-22/IL-22 receptor complex and inhibiting downstream signalling.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT00563524||Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis||Phase 1 Interventional||Wyeth is now a wholly owned subsidiary of Pfizer|
|NCT00883896||Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis||Phase 2 Interventional||Pfizer|
|NCT01941537||Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis||Phase 2 Interventional||Rockefeller University|